Trialjectory Appoints Gregory T. Simpson as Chief Marketing Officer


Mr. Simpson brings more than two decades of marketing and technology experience to the company, including leadership roles in the clinical cloud software space.

NEW YORK, July 6, 2022 /PRNewswire/ — Court case (“the Company”), the AI-based decision support platform for patients, healthcare providers and pharmaceutical companies, today announced that it has appointed Gregory T. Simpson as Chief Marketing Officer of the company, effective immediately. In this role, Mr. Simpson will lead Trialjectory’s overall marketing strategy and brand initiatives and report to Tzvia Baderco-founder and CEO of the company.

“Greg joins our team as a senior marketing and technology executive with strong leadership, technical and business skills that will help Trialjectory introduce itself to more patients, oncologists and pharmaceutical companies,” said Ms. Bader. “His experience will also allow us to further amplify our message that patient access to advanced cancer treatments needs to be democratized and that patient-centricity needs to be at the forefront of the drug development process for it to be successful. Trialjectory will benefit greatly from Greg’s guidance as we work to redefine healthcare to personalize it for every patient.”

Mr. Simpson most recently served as Senior Vice President and Head of Marketing at Saama Technologies, an AI-focused clinical cloud company, where he led its marketing strategy and execution. Prior to joining Saama, he served as Head of Integrated Marketing at Medidata Solutions (acquired by Dassault Systèmes), a cloud-based clinical trial software company. Additionally, Mr. Simpson worked as Chief Marketing Officer at Frontwave, where he built and led marketing for the cloud software startup. He has also held leadership positions at GTSE Consulting and AT&T.

“It bothered me that patients struggled to find advanced treatments, and Trialjectory is dedicated to improving the cancer treatment landscape as we know it today with its one-of-a-kind technology platform. that bridges the gap between patients and the pharmaceutical industry,” added Simpson. “As CMO, I look forward to working with Tzvia and the rest of the team to refine and advance the company’s marketing and brand roadmap as we seek to reimagine the patient experience and transforming the future of cancer care.”

Mr. Simpson currently serves on the board of directors of Affinity Federal Credit Union. He is a 2022 PM360 Elite 100 Award Winner, PR Daily Media Relations Award Recipient, a Viddy Gold Award, and more. He earned a Masters of Business Administration in Marketing from Seton Hall University and Master of Science in International Trade from Seton Hall University.

About Trialjectory

Trialjectory is an AI-powered decision support platform that democratizes access to advanced cancer treatments and addresses the multiple challenges facing the oncology drug development ecosystem. Its unique model informs and empowers cancer patients to take ownership of their treatment journey, supports a more personalized approach to patient care, and helps pharmaceutical companies achieve patient-centric drug development. Trialjectory has been recognized by TIME as one of “The 100 best inventions of 2020and named winner in the AI ​​and Data category for fast business‘s”2021 Ideas That Change the World Award.”

For more information, please visit www.trialjectory.comand follow the Company on Iinstagram, Facebook and LinkedIn.


View original content:

SOURCE Essayjectory


Comments are closed.